UPDATE: BTIG Downgrades Neuronetics (STIM) to Neutral on Q3 Revenue Shortfall
- Japan's Nikkei posts biggest point gain for fiscal year
- Citi downgrades tech stocks as its flagship indicator signals 'euphoria' levels
- UBS sees 5 warnings signals on semiconductor chip stocks
- 2 reasons why Tesla stock fell on Thursday
- US consumer sentiment tops estimates in March to hit nearly 3-yr high, UMich says
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Kerrisdale Capital is short Microstrategy (MSTR), long bitcoin
- AMC Entertainment (AMC) Enters $250M ATM Agreement
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Home Depot (HD) to Acquire SRS Distribution for $18.25B EV
Neuronetics (STIM) PT Lowered to $15 at Canaccord Genuity
October 13, 2021 8:06 AM EDTCanaccord Genuity analyst William Plovanic lowered the price target on Neuronetics (NASDAQ: STIM) to $15.00 (from $21.00) while maintaining a Buy rating on weaker Q3 revenue.
The analyst commented, "Neuronetics announced preliminary Q3/21 revenue of ~$13.8M, missing our $15.0M estimate, and the companys guidance of $15M-$16M. Management commentary from the preannouncement indicated... More
Neuronetics Inc. (STIM) Prelim. Q3 Revenue Falls Short of Prior Guidance
October 12, 2021 4:18 PM EDTNeuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today provided preliminary revenue results for the third quarter of 2021.
The Company expects total revenue for the third quarter to be approximately $13.8... More